MenidiMedica Greece is proud to announce the successful completion of preliminary laboratory trials of an experimental biotechnological formulation, hereinafter referred to as Poxivir, against different species of the genus Orthopoxvirus.
Poxivir is an experimental biotechnological formulation which acts as an inhibitor of Orthopoxvirus members.
Orthopoxvirus species can infect animals and humans. The members of Orthopoxvirus genus are camelpox, cowpox, ectromelia, horsepox, monkeypox, raccoonpox, skunkpox, taterapox, uasin gishu, vaccinia, variola, volepox.
The laboratory trials, conducted by MenidiMedica Greece, were divided into two phases:
- The investigation and exact indication of in vitro cell cytotoxic value of Poxivir against different Orthopoxvirus members, including monkeypox, cultivated in cell cultures.
- The lethal infection of several groups of mices with different Orthopoxvirus members, including monkeypox, in order to determine in vivo cytotoxicity of Poxivir in mice together with the proposed dosages, duration of treatment and protection from mortality with Poxivir.
In the next few days, MenidiMedica Greece will release a public statement with the obtained data of the experimental two (2) phases – without the announcement of the active substance(s) in Poxivir and will make a public invitation to whoever expresses the desire to participate into this project as a potential treatment of diseases caused by Orthopoxvirus members.
This press release will be promoted in print and electronic press, local and international.
In the next few days, an updated press release, will be followed, to local and international print and electronic press with the obtained experimental data.